By a GenomeWeb Staff Reporter

NEW YORK (GenomeWeb News) – Proteome Sciences today announced Takeda Pharmaceuticals has extended a contract to use PS Biomarker Services for the development of mass spectrometry-based assays for disease-related proteins.

Financial and other terms of the deal were not disclosed.

In a statement, Proteome Sciences said it will apply its capabilities in the discovery and validation of peptide and protein biomarkers and in assay development for research covered by the deal.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.